Last reviewed · How we verify

NCT04676503

Vaginal and Rectal Colonization of Lactobacillus Crispatus NTCVAG04 Following Oral Administration in Patients With History of Vaginitis/Vaginosis

Completed NA Last updated 21 December 2020
What this trial tests

NA trial testing BIOVAGINIL in Vaginitis in 20 participants. Completed in 21 July 2020.

Timeline
22 November 2019
Primary endpoint
27 May 2020
21 July 2020

Quick facts

Lead sponsorNTC srl
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment20
Start date22 November 2019
Primary completion27 May 2020
Estimated completion21 July 2020
Sites1 location across Italy

Drugs / interventions tested

Conditions studied

Sponsor

NTC srl — full company profile →

Who can join

18 and older, female only, with Vaginitis or Vaginosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to identify the presence of L. Crispatus in the rectum and vagina after oral administration of BIOVAGINIL by searching for specific DNA of the bacterial strain, to evaluate the tolerability of BIOVAGINIL and evaluate the minimum duration of the oral administration necessary to determine the appearance of L. Crispatus.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Vaginitis

Currently open trials in the same condition.

Other NTC srl trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04676503.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing